12:02 PM EDT, 06/24/2026 (MT Newswires) -- GSK (GSK) said Wednesday its Harmony Row Acquisition unit commenced a tender offer to purchase all outstanding Class A and Class B shares of Nuvalent ( NUVL ) for $124 per share in cash.

Following the consummation of the offer, the unit will merge into Nuvalent ( NUVL ), which will continue as a direct wholly-owned subsidiary of GlaxoSmithKline LLC.

Nuvalent's ( NUVL ) board of directors recommended that stockholders accept the offer and tender their shares, GSK said.

The tender offer and withdrawal rights will expire on July 14, the company added.

Price: 51.20, Change: -0.87, Percent Change: -1.67